Hepta Medical, a Suresnes, France-based medical device company, raised €5.7M in Series A funding.
The round was led by BPI France with participation from M&L Healthcare and Clery IG.
The company intends to use the funds for the 510(k) regulatory approval process for the first version of its microwave ablation platform for the start of its clinical trials.
Founded in 2019 by Sofinnova medtech acceleration team, MD Start and led by CEO Dr. Thomas Bancel, Hepta Medical develops a flexible microwave ablation platform for the minimally-invasive treatment of early-stage lung cancer patients. It is equipped with a proprietary patented tissue temperature sensor that enables monitoring of the growth of the ablation zone in-situ and in real-time during endobronchial ablation procedures. The device also incorporates predictive software, powered by artificial intelligence, which combines procedural CT images and temperature measurements to display the ablation zone in real-time to the clinician during the procedure.
The chairman of the board of directors, Gérard Hascoët, a Sofinnova Venture Partner, will be joined by Philippe Boucheron and Jocelyn Kum as representatives for BPI France and M&L Healthcare, respectively.
FinSMEs
04/09/2024